Last update April 15, 2024

Ciprofibrate

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Ciprofibrate, a fibric acid derivative, is a lipid-regulating drug with actions on plasma lipids similar to those of bezafibrate. It decreases elevated triglyceride levels by increasing the activity of lipases that catabolize triglyceride-rich lipoproteins and decreasing LDL cholesterol levels. It also increases HDL cholesterol levels (Miller 1998). Oral administration.

At the time of the last update we found no published data in relation to lactation. 

Its high binding to plasma proteins makes its passage into milk unlikely. 

Due to serious side effects in patients treated with ciprofibrate, it is not marketed in many countries or restrictions have been imposed on its approved indications.

In case of administering a fibrate during lactation, it is advisable to choose those with a shorter half-life: Bezafibrate, Gemfibrozil. 

For considerations on the appropriateness of lipid-lowering treatment during lactation see Maternal hyperlipidemia, hypercholesterolemia, hypertriglyceridemia.


See below the information of this related product:

Alternatives

  • Bezafibrate (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Colesevelam Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Colestipol Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Colestyramine (Safe substance and/or breastfeeding is the best option.)
  • Ezetimibe (Safe substance and/or breastfeeding is the best option.)
  • Gemfibrozil (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Pravastatin Sodium (Safe substance and/or breastfeeding is the best option.)
  • Rosuvastatin Calcium (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ciprofibrate in other languages or writings:

Group

Ciprofibrate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Ciprofibrate in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 289 daltons
Protein Binding 95 %
pKa 3.69 -
Tmax 1 - 4 hours
38 - 86 hours

References

  1. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Abstract

Total visits

18,837

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM